503 related articles for article (PubMed ID: 27389313)
1. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Buettner R
Mod Pathol; 2016 Oct; 29(10):1165-72. PubMed ID: 27389313
[TBL] [Abstract][Full Text] [Related]
2. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Scheel AH; Baenfer G; Baretton G; Dietel M; Diezko R; Henkel T; Heukamp LC; Jasani B; Jöhrens K; Kirchner T; Lasitschka F; Petersen I; Reu S; Schildhaus HU; Schirmacher P; Schwamborn K; Sommer U; Stoss O; Tiemann M; Warth A; Weichert W; Wolf J; Büttner R; Rüschoff J
Histopathology; 2018 Feb; 72(3):449-459. PubMed ID: 28851100
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Brunnström H; Johansson A; Westbom-Fremer S; Backman M; Djureinovic D; Patthey A; Isaksson-Mettävainio M; Gulyas M; Micke P
Mod Pathol; 2017 Oct; 30(10):1411-1421. PubMed ID: 28664936
[TBL] [Abstract][Full Text] [Related]
4. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
5. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
[TBL] [Abstract][Full Text] [Related]
6. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
Wang X; He J; Li J; Wu C; Yue M; Niu S; Jia Y; Jia Z; Cai L; Liu Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):43. PubMed ID: 38280970
[TBL] [Abstract][Full Text] [Related]
7. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.
Shi L; Zhang SJ; Chen J; Lu SX; Fan XJ; Tong JH; Chow C; Tin EK; Chan SL; Chong CC; Lai PB; To KF; Wong N; Chan AW
Mod Pathol; 2019 Nov; 32(11):1646-1656. PubMed ID: 31231126
[TBL] [Abstract][Full Text] [Related]
8. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
[TBL] [Abstract][Full Text] [Related]
9. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
[TBL] [Abstract][Full Text] [Related]
10. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB;
Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604
[TBL] [Abstract][Full Text] [Related]
11. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
12. Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
Koomen BM; Badrising SK; van den Heuvel MM; Willems SM
Histopathology; 2020 May; 76(6):793-802. PubMed ID: 31793055
[TBL] [Abstract][Full Text] [Related]
13. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Wang C; Hahn E; Slodkowska E; Eskander A; Enepekides D; Higgins K; Vesprini D; Liu SK; Downes MR; Xu B
Hum Pathol; 2018 Dec; 82():131-139. PubMed ID: 30075156
[TBL] [Abstract][Full Text] [Related]
15. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
17. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
